A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease - PubMed (original) (raw)

doi: 10.1186/1476-5926-1-3.

Françoise Imbert-Bismut, Djamila Messous, Gilles Antoniotti, Didier Benchetrit, Philippe Cart-Lamy, Gilles Delaporte, Danièle Doutheau, Théo Klump, Michel Sala, Didier Thibaud, Elisabeth Trepo, Dominique Thabut, Robert P Myers, Thierry Poynard

Affiliations

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease

Philippe Halfon et al. Comp Hepatol. 2002.

Abstract

BACKGROUND: Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are an alternative to liver biopsy in patients with chronic hepatitis C. Our aim was to assess the inter-laboratory variability of these tests, and their 6 components (gamma-glutamyl transpeptidase, alanine aminotransferase, alpha2-macroglobulin, haptoglobin, apolipoprotein A1, and total bilirubin) and to identify factors associated with this variability. RESULTS: Serum of 24 patients with chronic hepatitis C or severe alcoholic liver disease were prospectively recorded and analyzed in one reference center and in 8 additional laboratories. When gamma-glutamyl transpeptidase and alanine aminotransferase were expressed in international units, there was no significant difference between laboratories in the results of FibroTest or ActiTest; kappa statistics were greater than 0.50 with only 0.8% of cases (3/384) with a discordance of more than one stage. The main factor significantly associated with variability was the expression of gamma-glutamyl transpeptidase and alanine aminotransferase, as multiples of upper limit of reference values. The use of standardized method with pyridoxal phosphate reduced the variability of alanine aminotransferase expression, and standardized original Szasz method reduced the variability of gamma-glutamyl transpeptidase expression. CONCLUSIONS: The variability of FibroTest and ActiTest was acceptable without clinical consequences for the prediction of the stage of liver fibrosis and grade of activity. Standardized methods and assay calibration should be used and expression of alanine aminotransferase and gamma-glutamyl transpeptidase in multiples of the upper limit of reference values should not be employed.

PubMed Disclaimer

Figures

Figure 1

Figure 1

FibroTest and ActiTest variability according to laboratories (centers) and units of enzymatic expression: international units (IU) and upper limit of normal (UNL).

Figure 2

Figure 2

Serum proteins and total bilirubin variability according to laboratory (center).

Figure 3

Figure 3

Alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (GGT) variability according to laboratory and units of enzymatic expression: international units (IU) and upper limit of normal (UNL).

References

    1. EASL International Consensus Conference on hepatitis C. Paris 26–27 February 1999 Consensus statement. J Hepatol. 1999;31:3–8. doi: 10.1016/S0168-8278(99)80367-5. - DOI - PubMed
    1. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol. 2000;14:543–548. - PubMed
    1. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986;1 (8480):523–525. doi: 10.1016/S0140-6736(86)90883-4. - DOI - PubMed
    1. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, for the MULTIVIRC group Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069–1075. doi: 10.1016/S0140-6736(00)04258-6. - DOI - PubMed
    1. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F. Biochemical markers of liver fibrosis in patients infected by Hepatitis C Virus: Longitudinal validation in a randomized trial. J Viral Hepatitis. 2002;9:128–133. doi: 10.1046/j.1365-2893.2002.00341.x. - DOI - PubMed

LinkOut - more resources